Stereotactic Planning Software Market | Competitive Structure, Company Positioning, Supplier Strength and Forecast
Stereotactic Planning Software Competition Is Concentrated Around Planning Accuracy, Installed Systems, and Clinical Workflow Control
The Stereotactic Planning Software market is supplier-concentrated rather than fully fragmented, with demand shaped by neurosurgery departments, radiation oncology centers, cancer hospitals, Gamma Knife and LINAC users, and image-guided surgery programs that require validated planning, dose optimization, image fusion, segmentation, and treatment-review tools. The global Stereotactic Planning Software market is estimated at about USD 316 million in 2026, rising at a CAGR of nearly 4.2% to reach about USD 458 million by 2035, with integrated planning platforms taking a stronger position than stand-alone tools because hospitals increasingly prefer connected workflows across MRI, CT, angiography, contouring, stereotactic radiosurgery, and treatment delivery. Competition is led by platform-linked suppliers such as Brainlab, Elekta, Siemens Healthineers/Varian, Accuray, and specialized surgical navigation or radiation planning companies, while smaller vendors compete mainly through procedure-specific modules, integration support, planning automation, and service responsiveness.
Supplier ecosystem is led by platform owners, not isolated software sellers
Stereotactic Planning Software does not behave like a general hospital IT category. Buyer preference is closely tied to the installed base of radiosurgery equipment, neurosurgical navigation platforms, oncology treatment planning systems, and vendor-certified clinical workflows. This gives system-linked suppliers a stronger position because the software has to work with imaging datasets, coordinate systems, beam models, immobilization methods, dose engines, QA workflows, and clinical documentation.
Brainlab is one of the clearest examples of this competitive model. Its Elements portfolio covers cranial planning, radiosurgery planning, target definition, image fusion, distortion correction, organ-at-risk segmentation, target delineation, fiber tracking, and trajectory planning. The company’s broader digital ecosystem is present across thousands of hospitals globally, which gives it customer access beyond a single software license. In Stereotactic Planning Software, this matters because neurosurgeons and radiation oncologists do not buy only planning screens; they buy reproducibility, training, clinical confidence, and vendor support around difficult cases such as brain metastases, trigeminal neuralgia, spine metastases, AVMs, and functional neurosurgery.
Elekta’s strength is different. It is closely tied to Leksell Gamma Knife and GammaPlan-type workflows, where the installed base acts as a natural demand anchor. Gamma Knife users require planning software that is tightly connected to dose delivery, patient positioning, frame-based or frameless treatment, and long-term clinical evidence. This makes Elekta stronger in intracranial radiosurgery centers that already operate Gamma Knife systems or plan to upgrade existing radiosurgery programs.
Varian, now under Siemens Healthineers, competes through a broader radiation oncology software environment. Eclipse is not only a stereotactic planning tool; it is a comprehensive treatment planning system for photon, proton, electron, and brachytherapy workflows. Its strength in stereotactic use comes from integration with LINAC-based SRS and SBRT, HyperArc, RapidPlan, AI contouring, plan checking, scripting, and automation. This gives Varian a stronger position in multi-treatment cancer centers where stereotactic planning is one use case within a larger radiation oncology department.
Accuray competes from the robotic radiosurgery and precision radiotherapy side through CyberKnife and Radixact ecosystems. Its software demand is linked to hospitals using robotic beam delivery, image guidance, and tumor tracking. The company’s position depends heavily on new system placements, service revenue, and maintaining clinical confidence in highly specialized radiosurgery workflows.
Product categories split between integrated platforms, procedure-specific modules, and services
The stronger category in Stereotactic Planning Software is integrated planning because large hospitals prefer fewer workflow breaks between image import, fusion, segmentation, target definition, dose calculation, plan review, and treatment export. Stand-alone planning software still has a role in smaller centers, research settings, and procedure-specific adoption, but it is less competitive where hospitals want vendor accountability across the full treatment chain.
The major product and service categories include:
| Category | Main buyer logic | Stronger supplier type |
| Integrated stereotactic planning platforms | One workflow across imaging, contouring, dose, review, and delivery | Brainlab, Varian, Elekta |
| Cranial SRS planning modules | Brain metastases, AVM, trigeminal neuralgia, skull-base tumors | Brainlab, Elekta, Varian |
| Spine and extracranial planning modules | SBRT, spine metastases, high-dose precision treatment | Brainlab, Varian, Accuray |
| Image fusion and segmentation tools | MRI/CT/angiography alignment, organ-at-risk mapping | Brainlab, Varian, AI-enabled vendors |
| Services and implementation | Training, commissioning, updates, clinical support, QA setup | Installed-base vendors and regional distributors |
The services layer is commercially important because stereotactic planning is not simply installed and used. Hospitals need commissioning support, physicist training, contouring protocol alignment, planning template setup, cybersecurity review, and periodic software validation. This makes service access a competitive filter, especially in emerging markets where centers may buy advanced treatment systems but lack deep in-house planning experience.
Customer demand is strongest in cancer centers and neurosurgery-led radiosurgery programs
The largest customer groups are tertiary hospitals, oncology networks, academic medical centers, neurosurgery institutes, cancer research hospitals, and specialized radiation therapy centers. These buyers value planning accuracy, speed, reproducibility, regulatory clearance, image compatibility, integration with delivery equipment, and vendor training.
Cancer centers are the strongest customer group because stereotactic radiosurgery and stereotactic body radiotherapy require precise treatment planning for high-dose delivery in one to five fractions. Brain metastases, spine metastases, lung lesions, liver lesions, prostate lesions, and recurrent tumors increase the need for software that reduces contouring variation and improves treatment planning consistency. Neurosurgery-led demand is more specialized but highly valuable, especially where planning software supports biopsy trajectories, DBS lead placement, lesion targeting, fiber tracking, and function-preserving surgery.
In mature markets, customer access is shaped by installed equipment and replacement cycles. A hospital using Gamma Knife will usually stay within Elekta’s planning environment. A LINAC-heavy oncology network is more likely to standardize on Varian/Eclipse or a compatible third-party planning ecosystem. A neurosurgery department with Brainlab navigation may extend its software use into radiosurgery and cranial planning. This makes cross-selling and installed-base expansion more important than pure price competition.
Recent quantified developments show why supplier strength is tied to installed base and approvals
In June 2025, the U.S. FDA listed Brainlab’s RT Elements 4.5 under 510(k) K250440, covering Multiple Brain Mets SRS, Cranial SRS, Spine SRS, Cranial SRS with cones, dose review, retreatment review, segmentation, AI tumor segmentation, and object management modules. This type of clearance strengthens Brainlab’s position because hospital buyers can evaluate a broader validated module set rather than separate unconnected tools.
In September 2025, Elekta announced that Leksell Gamma Knife had treated its two millionth patient, supported by approximately 360 systems installed in more than 60 countries and more than 450 patients treated every day. This installed base directly supports Stereotactic Planning Software demand because each Gamma Knife program requires planning, dose review, workflow upgrades, training, and software maintenance.
In August 2025, Accuray reported fiscal 2025 revenue of USD 458.5 million, including USD 220.9 million in service revenue and an order book-to-bill ratio of 1.2. The service mix matters for planning software because robotic radiosurgery customers require long-term support, software upgrades, clinical training, and system uptime rather than one-time equipment delivery.
Varian’s Eclipse v18.1 also reflects the competitive direction of the market. The platform includes SRS support through HyperArc, enhanced imaging capabilities, plan review improvements, AI contouring for more than 200 anatomical structures, plan checking, and scripting through ESAPI. This makes Varian stronger in high-throughput radiation oncology departments where stereotactic planning must fit within broader treatment planning operations.
Competitive constraints are clinical validation, interoperability, cost, and planning workforce capacity
The Stereotactic Planning Software market is adoption-constrained by more than budget. Hospitals must validate dose models, verify image registration accuracy, train neurosurgeons and physicists, maintain cybersecurity compliance, and prove that planning automation is clinically acceptable. These requirements slow supplier switching because treatment teams do not easily replace familiar planning systems once clinical templates and QA procedures are established.
Interoperability is another constraint. A planning system may be technically advanced but commercially limited if it does not connect smoothly with MRI, CT, PACS, oncology information systems, LINACs, Gamma Knife systems, robotic radiosurgery platforms, QA software, and hospital IT infrastructure. This favors companies with broad installed ecosystems and weakens niche vendors unless they offer clearly superior modules.
Cost also affects adoption in mid-sized hospitals. Integrated software, annual maintenance, user training, hardware requirements, implementation support, and upgrades create a recurring spending burden. In lower- and middle-income regions, many hospitals first invest in imaging equipment or treatment systems and delay advanced planning modules until procedure volume justifies the software cost.
The strongest suppliers are therefore not simply those with the most advanced algorithm. They are companies that combine validated planning capability, installed equipment relationships, regulatory clearance, training capacity, clinical references, and regional service support. In Stereotactic Planning Software, buyer trust is built case by case, and supplier position improves when hospitals can use the same planning environment across more patients, more lesions, more treatment sites, and more clinical teams.
Supplier Segmentation in Stereotactic Planning Software Is Defined by Installed Systems, Clinical Modules, and Service Reach
The supplier base for Stereotactic Planning Software can be segmented into four practical groups: radiosurgery system-linked software providers, radiation oncology planning platform vendors, neurosurgical navigation and digital surgery companies, and specialist module or integration providers. The strongest group is system-linked and platform-linked suppliers because hospitals prefer planning tools that are already validated with Gamma Knife, LINAC, CyberKnife, robotic positioning, imaging, dose calculation, and oncology information systems. This makes the market less open to low-cost software-only entrants than general hospital software markets.
The first supplier group is built around dedicated radiosurgery ecosystems. Elekta is the clearest example because Gamma Knife planning demand is linked directly to the Leksell Gamma Knife installed base. Gamma Knife users require planning software that supports intracranial indications, frame-based and frameless workflows, dose shaping, treatment review, and long-term support. This gives Elekta high customer retention where the buyer already operates a Gamma Knife platform.
The second group includes broad radiation oncology planning vendors. Varian, now part of Siemens Healthineers, is strong in this category because Eclipse is used across conventional radiotherapy, IMRT, VMAT, SRS, SBRT, proton planning, brachytherapy, and oncology workflow integration. These platforms are preferred by cancer centers that want one planning environment for multiple treatment types rather than separate tools for every clinical indication.
The third group is formed by digital surgery and image-guidance companies. Brainlab fits this category through Elements, ExacTrac, Curve, Buzz, Loop-X-related imaging integration, and neurosurgical navigation links. Its advantage is portfolio depth across radiosurgery, surgery, imaging, and planning. This makes Brainlab relevant for hospitals where neurosurgery and radiation oncology both influence software selection.
The fourth group includes specialized treatment planning, imaging, segmentation, AI contouring, quality assurance, and workflow integration providers. These suppliers usually do not control delivery equipment, but they compete through automation, interoperability, contouring speed, image fusion quality, or hospital-specific customization. Their strongest opportunity is in hospitals that already own treatment systems but need better planning productivity, segmentation consistency, or review tools.
Portfolio depth is stronger where planning, delivery, and follow-up are connected
Product depth in this market is not measured only by the number of software modules. It is measured by how many clinical steps a supplier can control. The deeper portfolios cover image import, MRI/CT fusion, distortion correction, target contouring, organ-at-risk segmentation, dose optimization, plan review, retreatment analysis, export to delivery system, and post-treatment documentation.
Integrated planning platforms are stronger than stand-alone modules for larger hospitals because clinical accountability is concentrated in one workflow. A high-volume oncology center treating brain metastases, spine metastases, lung lesions, and prostate SBRT cases cannot rely on fragmented software tools if each tool requires separate validation and IT support. For this reason, integrated solutions account for the largest share of demand, while modular software performs better in hospitals looking to upgrade one workflow bottleneck, such as AI segmentation or image fusion.
Product segmentation can be read through practical hospital use:
| Segment | Buyer need | Stronger supplier position |
| Cranial SRS planning | Brain metastases, AVM, meningioma, trigeminal neuralgia, vestibular schwannoma | Elekta, Brainlab, Varian |
| Spine SRS/SBRT planning | Spine metastases, high-dose conformal treatment, cord sparing | Brainlab, Varian, Accuray-linked workflows |
| Multi-lesion planning | Multiple brain metastases, single-isocenter planning, plan efficiency | Brainlab, Varian |
| Robotic radiosurgery planning | Motion tracking, non-isocentric beam delivery, prostate/lung SBRT | Accuray ecosystem |
| AI contouring and segmentation | Faster contouring, reduced inter-user variation, organ-at-risk mapping | Varian, Brainlab, specialist AI vendors |
| Service and implementation | Commissioning, training, upgrades, QA workflow, cybersecurity support | Installed-base suppliers |
Regional availability is strongest where radiosurgery equipment density is high
North America remains the most attractive region for Stereotactic Planning Software because the United States has a dense base of academic hospitals, private cancer centers, radiation oncology networks, and neurosurgery institutes. The region also has faster uptake of LINAC-based SRS/SBRT, AI contouring, multi-metastases planning, and software support contracts. Buyers in the U.S. tend to value automation, reimbursement-linked throughput, physician productivity, and documentation quality. This gives Varian, Brainlab, Elekta, and Accuray strong access through direct sales, clinical training teams, and equipment-linked service contracts.
Europe is supplier-rich and clinically mature, but adoption behavior is more procurement-controlled. Germany, Sweden, France, the U.K., Italy, Spain, and the Netherlands represent strong demand clusters because they have established radiotherapy infrastructure, specialist neurosurgery centers, and public hospital procurement systems. Germany is particularly relevant because Brainlab is headquartered in Munich and has a strong European clinical reference base. Sweden matters because Elekta’s Gamma Knife heritage and Karolinska-linked clinical history continue to influence radiosurgery credibility.
Asia Pacific is growing through hospital capacity expansion, cancer burden, private oncology investment, and public radiotherapy modernization. Japan, South Korea, China, India, Australia, and Singapore represent different demand patterns. Japan and South Korea are technology-intensive markets with advanced radiosurgery adoption. China has large hospital infrastructure and procurement scale, but software buying is shaped by hospital tendering, localization expectations, and regulatory approval. India remains price-sensitive but increasingly active in high-end cancer care, especially large private hospital chains and tertiary public institutes.
The Middle East is a smaller but high-value regional cluster because large hospital projects in Saudi Arabia, the UAE, Qatar, and Kuwait often procure advanced oncology equipment as part of tertiary healthcare investment. In these markets, supplier access depends heavily on distributor capability, local service coverage, training availability, and the ability to support imported equipment over long contract periods. Latin America and Africa remain more constrained by radiotherapy access gaps, capital budgets, physicist availability, and maintenance infrastructure, although leading hospitals in Brazil, Mexico, South Africa, Egypt, and Turkey continue to invest in advanced oncology tools.
Channel structure is direct-led for enterprise hospitals and distributor-led for service-limited regions
Stereotactic Planning Software is mostly sold through direct enterprise sales, equipment-linked contracts, software upgrade packages, service agreements, and hospital procurement tenders. A typical sale may involve clinical demonstrations, physicist evaluation, IT security review, compatibility assessment, regulatory documentation, and user training before final purchase. This makes the sales cycle longer than standard software procurement.
In the United States and Western Europe, suppliers usually control customer relationships directly. The commercial discussion is often tied to installed hardware, software upgrades, annual maintenance, clinical training, and multi-site standardization. In Asia Pacific, the Middle East, Latin America, and Africa, channel partners and distributors remain more important because hospitals need local installation, language support, procurement navigation, spare-part coordination for related hardware, and response support.
Replacement behavior is also different from hardware replacement. Hospitals rarely replace stereotactic planning systems only because a newer interface exists. They upgrade when the current software cannot support new clinical protocols, additional lesion volumes, AI contouring, faster planning, new delivery systems, cybersecurity requirements, or multi-site workflow standardization. This makes software maintenance and upgrade revenue important for suppliers with large installed bases.
Leading Stereotactic Planning Software Companies Compete Through Clinical Trust, Integration, and Installed-Base Advantage
Brainlab holds a top-tier position in Stereotactic Planning Software through its Elements portfolio and its broader digital surgery ecosystem. Its advantage is strongest where hospitals want planning tools linked to image fusion, segmentation, cranial SRS, spine SRS, retreatment review, object management, and neurosurgical workflows. Brainlab is also positioned beyond radiation oncology because its technology is used in neurosurgery, spine surgery, operating rooms, imaging, and digital health. This gives the company cross-department access inside hospitals, which is commercially important because stereotactic planning decisions often involve neurosurgeons, radiation oncologists, physicists, radiologists, and hospital IT teams.
Elekta is strongest in Gamma Knife-linked planning. Its competitive position is built around Leksell Gamma Knife, GammaPlan-related planning workflows, stereotactic radiosurgery evidence, and long-term intracranial treatment experience. Elekta does not compete only on software functionality; it competes on the installed clinical ecosystem. Hospitals using Gamma Knife generally require software compatibility, treatment planning reliability, system updates, training, and service continuity. This gives Elekta a defensible position in intracranial radiosurgery even when broader radiation oncology departments use other planning systems.
Varian, under Siemens Healthineers, has one of the broadest radiation oncology software positions through Eclipse, ARIA, HyperArc, Ethos-linked adaptive workflows, AI contouring, and treatment planning automation. Varian’s strength is higher in LINAC-heavy oncology centers where SRS and SBRT are part of a wider radiotherapy workload. Its software is attractive to multi-site cancer networks because one platform can support conventional radiotherapy, stereotactic radiotherapy, proton therapy, brachytherapy planning, and oncology information management. The company’s advantage is not narrow stereotactic specialization but department-wide standardization.
Accuray’s position is linked to CyberKnife and Radixact system users. Its planning and workflow advantage comes from robotic radiosurgery, real-time tracking, tumor motion management, and precise SBRT treatment delivery. Accuray is stronger in centers that market robotic radiosurgery capabilities or use CyberKnife for prostate, lung, spine, brain, and complex lesion treatment. Its service revenue base is important because buyers expect system uptime, upgrades, training, and technical support across long equipment lifecycles.
RaySearch Laboratories is a relevant independent software participant through RayStation, which supports treatment planning across multiple modalities including photon, electron, proton, carbon ion, boron neutron capture therapy, and adaptive workflows. Its competitive role differs from equipment-tied vendors because it can serve centers looking for vendor-neutral planning capability. This is useful in advanced radiotherapy centers, proton centers, and academic hospitals that want flexibility across delivery platforms.
MIM Software, now part of GE HealthCare, is important in imaging, contouring, image registration, dosimetry, and oncology workflow support. Its strength is less about owning stereotactic delivery systems and more about improving imaging-driven planning workflows. This makes it relevant where hospitals need contouring, deformable registration, PET/CT or MRI-based planning support, dose accumulation, and multi-modality review.
Mirada Medical, Limbus AI, MVision AI, and other AI contouring or imaging workflow vendors participate around segmentation productivity. These companies are not always positioned as full Stereotactic Planning Software suppliers, but they influence buyer behavior because contouring workload is one of the bottlenecks in SRS and SBRT planning. In high-volume centers, saving even 10–20 minutes per case can matter if the department is treating hundreds or thousands of stereotactic cases annually.
Pricing behavior is shaped by module depth, number of users, number of workstations, integration needs, clinical applications, maintenance contract, and installed-equipment relationship. Large hospitals usually buy through bundled enterprise contracts, while smaller centers may license specific modules. Service costs are not secondary: commissioning, physicist validation, version upgrades, cybersecurity documentation, and training can affect the real cost of ownership. This is why low software license pricing alone rarely wins in clinical stereotactic planning.
Recent developments affecting supplier position include:
- June 2025: Brainlab received U.S. FDA 510(k) clearance for RT Elements 4.5, including Multiple Brain Mets SRS, Cranial SRS, Spine SRS, Cranial SRS with cones, dose review, retreatment review, segmentation, AI tumor segmentation, SmartBrush, and object management modules. This widened its validated module base for radiosurgery planning.
- June 2025: Brainlab set an IPO price range of EUR 80–100 per share, targeting a market capitalization of up to EUR 2.1 billion and an issue volume of up to EUR 520 million. The planned capital allocation signaled further expansion of digital medical technology portfolios.
- September 2025: Elekta announced that Leksell Gamma Knife had crossed two million treated patients globally, supported by around 360 systems in more than 60 countries. This reinforced Elekta’s installed-base advantage in intracranial radiosurgery planning.
- August 2025: Accuray reported fiscal 2025 revenue of USD 458.5 million, including USD 220.9 million in service revenue and a 1.2 order book-to-bill ratio. The service-heavy profile supports long-term software, training, and maintenance demand across CyberKnife and Radixact users.
- 2025: Varian’s Eclipse v18.1 continued to strengthen stereotactic planning through HyperArc support, AI contouring for more than 200 anatomical structures, plan review tools, scripting, and workflow automation for high-throughput radiation oncology departments.